Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts. Show More...
-
Website https://www.summittxinc.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 18.22 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-01 2011-01 2012-01 2013-01 2014-01 2015-01 2016-01 2017-01 2018-01 2019-01 TTM Earnings Per Share GBP -0.41 -0.14 -0.08 -1.35 -1.5 -1.45 -1.7 -1.75 -1.55 0.45 -0.85 Dividends GBP Payout Ratio % * Shares Mil 13.0 33.0 36.0 3.0 4.0 85.0 12.0 12.0 13.0 17.0 29.0 Book Value Per Share * USD 1.07 Free Cash Flow Per Share * USD Return on Assets % -42.59 -56.52 -59.95 -102.14 -110.7 -87.32 -76.85 -68.21 -15.58 13.24 -50.71 Financial Leverage (Average) 1.39 1.38 1.62 1.54 1.39 1.3 1.19 5.46 1.4 1.46 Return on Equity % -64.39 -78.45 -88.56 -160.74 -160.07 -115.2 -94.67 -242.3 -223.47 28.72 -77.76 Return on Invested Capital % -63.74 -78.63 -88.68 -161.13 -160.28 -115.66 -94.81 -234.25 -223.7 28.71 -67.16 Interest Coverage -85.85 -998.33 -28.82 Current Ratio 6.01 3.09 2.06 2.74 1.65 4.03 6.51 3.06 1.89 3.63 3.26 Quick Ratio 5.89 2.95 2.0 2.37 1.13 3.05 5.18 2.61 1.31 2.56 2.81 Debt/Equity 0.010